Blog
RSS FeedPosted by Michael Wonder on 21 Oct 2024
Drug price negotiations for obstructive hypertrophic cardiomyopathy drug Camzyos stall, delaying reimbursement
21 October 2024 - Urgent attention is on the drug price negotiations for the obstructive hypertrophic cardiomyopathy (oHCM) treatment Camzyos ...
Posted by Michael Wonder on 10 Oct 2024
Pulmonary fibrosis drug Ofev nears key reimbursement decision in Korea
10 October 2024 - The Pharmaceutical Reimbursement Evaluation Committee under HIRA is reportedly set to review Ofev (nintedanib), a treatment ...
Posted by Michael Wonder on 05 Sep 2024
Tevimbra and Pemazyre pass cancer panel after rechallenge
29 August 2024 - BeiGene's anti-PD-1 immuno-oncology drug Tevimbra (tislelizumab) and Handok's FGFR inhibitor Pemazyre (pemigatinib) have passed the Cancer ...
Posted by Michael Wonder on 13 Aug 2024
Government, Lilly Korea turn a blind eye to Retevmo’s prohibitive cost
12 August 2024 - Patients are appealing to the government to cover the cost of Lilly Korea's Retevmo (selpercatinib), the ...
Posted by Michael Wonder on 08 Jul 2024
Besremi retries for insurance coverage promising a potential operational cure
8 July 2024 - Besremi (rofeginterferon alfa-2b), which has recently set a new standard in treating polycythemia vera by offering ...
Posted by Michael Wonder on 03 Jul 2024
CSL Behring’s haemophilia B drug Idelvion gets insurance coverage
2 July 2024 - CSL Behring's long-acting hemophilia B treatment Idelvion (albutrepenonacog alfa) has come to receive reimbursement in Korea. ...
Posted by Michael Wonder on 01 Jul 2024
Antengene announces Xpovio (selinexor) National Health Insurance Service approval for reimbursement in South Korea
26 June 2024 - The approval of Xpovio by the NHIS in South Korea is the fourth national reimbursement in the ...
Posted by Michael Wonder on 25 Jun 2024
Will Trodelvy get innovative new drug status backed by 100,000 petitions?
24 June 2024 - As the government will likely reflect innovative new drug values on its reimbursement criteria this year, ...
Posted by Michael Wonder on 15 Jun 2024
Extremely rare disease drug Ceprotin clears major hurdle to reimbursement
14 June 2024 - Ceprotin (protein C concentrate), an ultra-rare disease treatment developed by Takeda Pharmaceutical Korea, has passed the ...
Posted by Michael Wonder on 03 Jun 2024
Paediatric rare disease drug Qarziba gets green light for coverage
30 May 2024 - The Health Insurance Review and Assessment Service (HIRA) held its fourth Cancer Disease Review Committee (CDRC) ...
Posted by Michael Wonder on 29 May 2024
KRPIA urges incoming Assembly to recognise new drugs’ value
28 May 2024 - The Korean Research based Pharma Industry Association (KRPIA) called for the 22nd National Assembly, which is ...
Posted by Michael Wonder on 28 May 2024
Regulator OKs Eisai Korea’s Leqembi for early Alzheimer's disease treatment
27 May 2024 - Eisai Korea said its monoclonal antibody treatment Leqembi (lecanemab) has received approval from the Ministry of ...
Posted by Michael Wonder on 23 May 2024
Antengene's Xpovio moves close to getting insurance benefits
3 May 2024 - Xpovio (selinexor), the first drug launched in Korea by Antengene, has won recognition to receive reimbursement ...
Posted by Michael Wonder on 22 May 2024
Janssen Korea to cease supply of anti-fungal drug Sporanox
22 May 2024 - Janssen Korea will discontinue the supply of its anti-fungal drug Sporanox (itraconazole) solution. ...
Posted by Michael Wonder on 20 May 2024
Will Erbitux’s reimbursement be expanded to first-line treatment of colorectal cancer?
17 May 2024 - Attention is on whether Merck's colorectal cancer drug, Erbitux (cetuximab), can expand its reimbursement following the ...